By Michael Kokalari CFA, chief economist, and Thai Thi Viet Trinh, senior economist.

Understanding one of the fastest-growing asset classes

The rise and regulation of finfluencers

How to invest in the UK’s social impact REITs

What is AI slop and why should investors care?

Unlocking investment opportunities in blockchain equities

Unlocking investment opportunities in blockchain equities

In this interview, we discuss with Scancell Holdings’ chief medical officer, Dr Nermeen Varawalla, the evolving immune oncology landscape and the increasingly important role of therapeutic vaccines, in particular as combination treatments with immune checkpoint inhibitors (ICIs). Nermeen also highlights the company’s two distinct vaccine platforms and the recently presented promising Phase II data from Scancell’s lead asset iSCIB1+ in advanced melanoma, which supports accelerated progression to Phase III trials in 2026. Nermeen ended the interview outlining the upcoming catalysts for the company in the next 12– 18 months.

Scancell Holdings (AIM: SCLP) is a UK-based clinical-stage biotech company developing off-the-shelf active immunotherapies against cancer using two proprietary platforms, ImmunoBody (DNA vaccines) and Moditope (peptide vaccines). Its lead candidate from the ImmunoBody platform, iSCIB1+, has reported promising Phase II data in advanced melanoma, with clear synergies when combined with ICIs. Its lead asset from the Moditope platform, Modi-1, is being tested in solid tumours.

Unlocking investment opportunities in blockchain equities

Unlocking investment opportunities in blockchain equities

In this episode, our director of content, investment trusts Milosz Papst provides an update on BlackRock Latin American Investment Trust. After giving a quick refresher about the company, he discusses the Latin American investment backdrop, where valuations look very attractive. He then highlights the importance of upcoming election cycles, before delving into the managers’ views about the prospects for the region. Discussion then turns to the trust, starting with the stock selection process, where favoured companies tend to be high-quality businesses at reasonable valuations, which may be overlooked by other investors. He then provides information about the portfolio, where the managers are happy to invest in some of the smaller and non-index countries, although it is important to understand that a large part of the portfolio is likely to be made up of Brazilian and Mexican stocks as these two countries make up around 90% of the MSCI Emerging Markets Latin America Index, which is the trust’s benchmark. He highlights a few of the largest portfolio holdings before discussing performance, which has been positive this year in both absolute and relative terms. To wrap up the podcast, he focuses on the dividend policy, where income is an important element of the trust’s total return objective, and highlights the discount control mechanism, which includes a tender offer based on the trust’s performance and average discount over a four-year period ending 31 December 2025.

Listen on your preferred podcast player below:

• Apple Podcasts
• Spotify
• YouTube
• Zencastr

About Uncovering Trusts: Uncovering Trusts is a podcast run by Edison analysts, which is released every two weeks. Subscribe to hear analyst interviews on how investment trusts maximise returns while managing risks for investors.